绿帽社

Selection in the Best of the Liver Meeting 2021

Published on 24/11/2021

绿帽社 Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor鈥檚 key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH